Company Overview and News

 
SKP up at midday as recent selloff looks overdone

2018-09-04 thestar.com.my
KUALA LUMPUR: Shares in SKP Resources Bhd are higher at midday after Public Investment Bank, in a strategy report on Tuesday, said the recent selloff looked overdone.
7155

 
Trading ideas: Sapura Energy, CMS, Southern Steel, Dayang, Axiata

2018-08-27 thestar.com.my
KUALA LUMPUR: JF Apex Research expects Sapura Energy Bhd , Cahya Mata Sarawak Bhd (CMSB), Southern Steel Bhd , Dayang Enterprise Holdings Bhd and Axiata Group Bhd to be among the stocks to watch on Monday.
4634 2852 0146 5665 6888 5141 AXXTF 7155

 
Sapura Energy, PUC, Axiata, Cahya Mata Sarawak, Magnum, Southern Steel, Dayang Enterprise, SKP Resources, MMC, MSM, Pos Malaysia, Paramount and Adventa

2018-08-24 theedgemarkets
KUALA LUMPUR (Aug 24): Based on corporate announcements and news flow today, companies that will be in focus on Monday (Aug 27) may include: Sapura Energy Bhd, PUC Bhd, Axiata Group Bhd, Cahya Mata Sarawak Bhd, Magnum Bhd, Southern Steel Bhd, Dayang Enterprise Holdings Bhd, SKP Resources Bhd, MMC Corp Bhd, MSM Malaysia Holdings Bhd, Pos Malaysia Bhd, Paramount Corp Bhd and Adventa Bhd.
4634 2852 5665 6888 IDEA 5141 ICLQY AXXTF 5202 532822 7155

 
Lower revenue weighs on SKP Resources 1Q net profit

2018-08-24 theedgemarkets
KUALA LUMPUR (Aug 24): SKP Resources Bhd’s saw its net profit fall 22.84% to RM25.74 million or 2.07 sen a share in the first quarter ended June 30, 2018 (1QFY19) versus RM33.36 million or 2.71 sen a share last year due to lower sales from key existing customers.
BSMAF 7155 1818

 
SKP Resources Q1 net profit lower at RM25.83mil

2018-08-24 thestar.com.my
Plastics contract manufacturer SKP Resources Bhd's net profit fell by 22.6% to RM25.83mil from RM33.35mil a year ago due to a decline in its revenue.
7155

 
Thinking of the box, Denko eyes record-breaking earnings in FY2019

2018-07-02 theedgemarkets
Foo: At the end of the day I have to ensure the return on investment is there
7155

4
Trading ideas: CIMB, HLB, BIMB, MRCB, MyEG

2018-05-31 thestar.com.my
KUALA LUMPUR: JF Apex Research expects CIMB, Hong Leong Bank, BIMB Holdings Bhd and Malaysian Resources Corp Bhd and MyEG Services Bhd to be among the stocks to watch following their latest corporate results.
KPJHF 5258 5878 5819 5102 7155 5112

 
Small and mid cap stock bargains

2018-04-15 thestar.com.my
"You won’t see it going up in a straight line. However, the time to buy is when nobody is buying ... ," says Affin Hwang Asset Management Bhd managing director Teng Chee Wai.
0166 7155

4
VS Industry, SKP Resources and Denko share the same problems

2018-04-14 thestar.com.my
Three notable electronic manufacturing services (EMS) companies on Bursa Malaysia seem to be in the same predicament.
BSMAF 7155 1818

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...